UBS has once again found itself in the regulatory crosshairs, this time drawing an investigation by securities arbitration law firm, Dimond Kaplan & Rothstein, P.A. (DKR), according to a DKR statement.
The investigation centers on the recommendations and sales of currency and FX products at UBS, including its V10 Enhanced FX Carry Strategy. In particular, both individual and institutional investors, including hedge funds and pension funds, used the UBS V10 product. The high-yielding FX investment utilized advanced computer algorithms to minimize the risk of losses in periods of volatility.
Unfortunately, the aforementioned product has not performed as stipulated, with investors losing a significant amount of money. Consequently, DKR is investigating whether UBS misled investors in the marketing and selling of the complex V10 product.
Covid-19 Fallout: A Unique Opportunity for the FX Market!Go to article >>
Moreover, the US Justice Department is also investigating whether UBS misrepresented how currency transactions were priced within UBS’s V10 product offering. This scrutiny is another layer of the regulator’s broad-based investigation into manipulation in the foreign exchange market.
The announcement comes after several months of tranquility for UBS, which found itself subjected to intense scrutiny by regulators for its role in a lingering FX probe that convulsed the $5.3 trillion a day industry last year.
DKR has represented investors in claims against UBS involving complex FX carry trade strategies. The law firm is inviting those who lost money in the V10 product or other FX-related instruments at UBS to contact its office.
Last May, UBS settled in its on-going currency fixing manipulation, culminating in a settlement of $135 million and for assistance in future investigations with Hausfeld, an international claimants’ law firm.